Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

300529.SZ

STRONG BUYREMOVE

Jafron Biomedical Co.,Ltd. · Healthcare · China · $2.1B · Avg Vol: $14M/d

80
StockRank
Q
75
V
41
M
51
P/E (TTM)
22.3x
ROE
15.6%
D/E
0.3x
Dividend %
3.1%
Director Trades · 180d
None in 180d →
Buybacks · 180d
None in 180d →
AI CONVICTION THESIS

Jafron Biomedical is a leading Chinese medical device company specializing in hemoperfusion. While it possesses high margins and a solid domestic market share, it does not align with our CDMO pricing power theme or other global macro tailwinds.

COMPANY DESCRIPTION

Jafron Biomedical Co., Ltd. is a leading medical device manufacturer specializing in blood purification products, primarily hemoperfusion cartridges used for poisoning, kidney disease, and critical care. The company holds a dominant market share in China's hemoperfusion sector, protected by proprietary adsorption technology and extensive clinical validation. It operates as a high-margin niche leader with an expanding global footprint in extracorporeal life support therapies.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGR
Revenue368M284M396M297M-6.9%
EPS0.170.080.160.10-14.9%
Shares808M808M799M799M-1.1%
Debt189M248M205M183M-1.1%
Equity528M465M493M513M-1.0%
Op CF131M135M155M107M-6.6%
Inv CF-45M-37M-167M95M—
Fin CF-54M-67M-146M-83M—
Loading...
PRICE (1M)-19.6%
2.322.482.642.802.96May 8May 29Jun 18
SMA 50SMA 200
Close
$2.32
RSI (14)
25.4
52W High
$3.59
From 52W High
0.6%

SCORE BREAKDOWN

Quality
75
ROIC
14.5%84.1
ROE
15.6%83.8
GP/Assets
29.0%63.6
Op. Margin
47.5%98.0
FCF/Assets
5.2%71.6
Piotroski
—83.4
Int. Cover
13.3x68.4
D/E Ratio
0.34x40.9
Current Ratio
8.71x84.1
Value
41
P/E (TTM)
22.3x51.8
EV/EBITDA
13.8x30.6
P/FCF
350.4x23.6
P/B
3.5x34.1
P/S
6.5x33.7
Div Yield
3.1%72.0
Momentum
51
52W High %
65%47.6
RS 6M
-29%43.7
SMA 50/200
0.91x37.0
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+127%78.4
Q Growth
17%60.2

FUNDAMENTALS

Market Cap
$2.1B
P/E (Forward)
9.8x
Gross Margin
77.2%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 300529.SZ are excluded.

TickerCompanyMkt CapStockRankSignal
300529.SZJafron Biomedical Co.,Ltd.(you)$2.1B80STRONG BUY
688016.SSShanghai MicroPort Endovascular MedTech Co., Ltd.$1.9B88STRONG BUY
002901.SZDouble Medical Technology Inc.$2.5B70BUY
600587.SSShinva Medical Instrument Co.,Ltd.$1.2B84STRONG BUY
301363.SZMeHow Innovative Ltd.$2.1B65HOLD
301087.SZCofoe Medical Technology Co.,Ltd.$1.6B92STRONG BUY
603658.SSAutobio Diagnostics Co., Ltd.$2.8B94STRONG BUY
2190.HKZylox-Tonbridge Medical Technology Co., Ltd.$853M82STRONG BUY
1302.HKLifeTech Scientific Corporation$932M84STRONG BUY
300482.SZGuangzhou Wondfo Biotech Co.,Ltd$1.2B66BUY

Peer medians: ROE 4.7% · P/E 27.9x · Gross margin 53.0%

Jafron Biomedical Co.,Ltd. (300529.SZ) — Stock Score Summary

Jafron Biomedical Co.,Ltd. (300529.SZ) has a MoatMap StockRank of 80/100 based on Quality (75/100), Value (41/100), and Momentum (51/100) factor scores. The current signal is STRONG BUY. Jafron Biomedical is a leading Chinese medical device company specializing in hemoperfusion. While it possesses high margins and a solid domestic market share, it does not align with our CDMO pricing power theme or other global macro tailwinds.

Jafron Biomedical Co., Ltd. is a leading medical device manufacturer specializing in blood purification products, primarily hemoperfusion cartridges used for poisoning, kidney disease, and critical care. The company holds a dominant market share in China's hemoperfusion sector, protected by proprietary adsorption technology and extensive clinical validation. It operates as a high-margin niche leader with an expanding global footprint in extracorporeal life support therapies.

Key Financial Metrics

Price$2.32
Market Cap$2.1B
P/E (TTM)22.32
P/E (Forward)9.83
Price/Book3.52
Return on Equity15.6%
Return on Invested Capital14.5%
Debt/Equity33.56
Gross Margin77.2%
Operating Margin47.5%
Revenue Growth2.3%
Dividend Yield3.1%
Free Cash Flow$6M

Jafron Biomedical Co.,Ltd. operates in the Medical Devices industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Jafron Biomedical Co.,Ltd.’s (300529.SZ) StockRank?
MoatMap’s StockRank for Jafron Biomedical Co.,Ltd. (300529.SZ) is 80/100, with a Strong Buy signal. It is a composite of Quality (75), Value (41), and Momentum (51) factor ranks across MoatMap’s 20,000+ stock universe.
Does Jafron Biomedical Co.,Ltd. have an economic moat?
Jafron Biomedical Co.,Ltd. (300529.SZ) has a Quality factor score of 75/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Jafron Biomedical Co.,Ltd. a buy, hold, or sell?
MoatMap’s current signal for Jafron Biomedical Co.,Ltd. (300529.SZ) is Strong Buy, based on a StockRank of 80/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Jafron Biomedical Co.,Ltd. in?
Jafron Biomedical Co.,Ltd. (300529.SZ) operates in the Healthcare sector, specifically the Medical Devices industry (China).
Browse all ranked stocks300529.SZ deep dive reportAI ChampionsHow we score stocksSense-check another stock